Dr. Haut brings more than two decades of healthcare experience to AskBio and will lead its business development strategy and execution.
Category: News
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct UBE3A gene deficiency.
Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy
Kelly to oversee all manufacturing functions at AskBio and Viralgen and lead clinical- and commercial-scale production of AAV vectors for gene therapy.
CYTOO and AskBio Enter into Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
The companies will work together to develop an AAV-based screening platform derived from patient cells, with the goal to select a preclinical candidate.
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development
AAV industry veteran Anna Tretiakova, PhD, has joined AskBio as SVP, Product Development to lead preclinical translational research.
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
AskBio today introduced AskFirst™, its patient advocacy program for patients and their families, and announced that Matthew Alsante will lead the program.
AskBio To Present At The 38th Annual J.P. Morgan Healthcare Conference
AskBio today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, in San Francisco.
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease.
AskBio Receives “Best Venture Funding” Award from Southeast BIO
Recognition highlights $235 million investment fueling growth of company and its industry-leading gene therapy technology platform
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies
Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV
